OMRONEE
Live / Applied — First extension granted (statement of use) (as of 15 Oct 2025)
What this means for you
Not registered yet, but its 03 Dec 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98882749
- Mark type
- Stylized text
- Filed
- 03 Dec 2024
- Published for opposition
- 24 Jun 2025
- Attorney of record
- Kristen Ruisi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for use in the treatment of Tourette Syndrome; Pharmaceutical preparations and substances for use in the treatment of Restless Legs Syndrome with Augmentation; Pharmaceutical preparations and substances for use in the treatment of central nervous system disorders
Owner
- Emalex Biosciences, Inc., Chicago, IL, US
- Emalex Biosciences, Inc., Chicago, IL, US
Prosecution history
- 16 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Oct 2025 — SOU EXTENSION 1 GRANTED
- 15 Oct 2025 — SOU EXTENSION 1 FILED
- 15 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 24 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Jun 2025 — PUBLISHED FOR OPPOSITION
- 18 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 May 2025 — ASSIGNED TO EXAMINER
- 03 Dec 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Dec 2024 — NEW APPLICATION ENTERED